What is Claimed

1. An antisense oligonucleotide (ASO) comprising a contiguous nucleotide sequence up to 30 nucleotides in length, wherein the contiguous nucleotide sequence comprises at least one non-naturally occurring nucleoside, wherein the ASO is capable of reducing calcium/calmodulin-dependent protein kinase type II delta (CAMK2D) protein and/or CAMK2D transcript expression in a human cell, and wherein the contiguous nucleotide sequence comprises the sequence set forth in SEQ ID NO: 657, SEQ ID NO: 659, SEQ ID NO: 822, SEQ ID NO: 827, SEQ ID NO: 981, SEQ ID NO: 982, SEQ ID NO: 983, SEQ ID NO: 984, SEQ ID NO: 986, SEQ ID NO: 989, SEQ ID NO: 1247, SEQ ID NO: 1249, SEQ ID NO: 1326, SEQ ID NO: 1359, SEQ ID NO: 1363, SEQ ID NO: 1371, SEQ ID NO: 1387, SEQ ID NO: 1389, SEQ ID NO: 1390, SEQ ID NO: 1409, SEQ ID NO: 1415, SEQ ID NO: 1420, or SEQ ID NO: 1429.

2. The ASO of claim 1, wherein the ASO is a gapmer.

3. The ASO of claim 1, wherein the non-naturally occurring nucleoside is a sugar modified nucleoside.

4. The ASO of claim 3, wherein the non-naturally occurring nucleoside comprises a 2'-O-alkyl-RNA; 2'-O-methyl RNA (2'-OMe); 2'-alkoxy-RNA; 2'-O-methoxyethyl-RNA (2'-MOE); 2'-amino-DNA; 2'-fluoro-RNA; 2'-fluoro-DNA; arabino nucleic acid (ANA); 2'-fluoro-ANA; or bicyclic nucleoside analog (LNA).

5. The ASO of claim 3, wherein the sugar modified nucleoside is an affinity enhancing 2' sugar modified nucleoside.

6. The ASO of claim 5, wherein the affinity enhancing 2' sugar modified nucleoside is an LNA.

7. The ASO of claim 1, wherein the ASO comprises one or more 5'-methyl-cytosine nucleobases.

8. The ASO of claim 1, wherein the contiguous nucleotide sequence comprises one or more modified internucleoside linkages.

9. The ASO of claim 8, wherein the one or more modified internucleoside linkages is a phosphorothioate linkage.

10. A conjugate comprising the ASO of claim 1, wherein the ASO is covalently attached to at least one non-nucleotide or non-polynucleotide moiety.

11. A pharmaceutical composition comprising the ASO of claim 1 and a pharmaceutically acceptable diluent, carrier, salt, or adjuvant.

12. A kit comprising the ASO of claim 1 and instructions for use.

13. The ASO of claim 6, wherein the LNA is constrained ethyl nucleoside (cEt), 2′,4′-constrained 2′-O-methoxyethyl (cMOE), α-L-LNA, β-D-LNA, 2′-0,4′-C-ethylene-bridged nucleic acids (ENA), amino-LNA, oxy-LNA, thio-LNA, or any combination thereof.

14. The ASO of claim 6, wherein the LNA is β-D-LNA or oxy-LNA.

15. The ASO of claim 1, wherein the contiguous nucleotide sequence comprises the sequence set forth in SEQ ID NO: 1390.

16. The ASO of claim 1, wherein the contiguous nucleotide sequence comprises the sequence set forth in SEQ ID NO: 657 or SEQ ID NO: 659.

17. The ASO of claim 1, wherein the ASO is capable of reducing CAMK2D protein and/or CAMK2D transcript expression in the human cell by at least about 20% compared to a corresponding cell not exposed to the ASO.